British medtech company Smith+Nephew has announce the launch of its REGENETEN Bioinductive Implant allowing access to thousands of patients in Japan. With more than 100,000 procedures completed globally since its introduction in the US and Europe, REGENETEN has had a transformative impact on the way surgeons approach rotator cuff repair.

The biocompatible and purified collagen-based REGENETEN Bioinductive Implant induces new tendon-like growth by taking advantage of natural wound healing processes which can help create an environment conducive to healing. Delivered arthroscopically through a small incision over the location of the damaged rotator cuff, the implant is about the size of a postage stamp and is completely resorbed within six months.

With more than 18 published clinical studies conducted globally, the REGENETEN Bioinductive Implant arrives in Japan with extensive clinical evidence covering the entire spectrum of rotator cuff disease, from partial thickness tears to large (3-5cm) and massive (5cm+) full-thickness tears. Additionally, with the potential to aid approximately 14,000 annual rotator cuff procedures in Japan, REGENETEN provides a patient-centric treatment shown to change the course of tear progression, aid return to normal activity, and reduce re-tears versus conventional surgery by up to 86%.

The REGENETEN Bioinductive Implant is part of Smith+Nephew's comprehensive Advanced Healing Solutions portfolio - redefining biological healing in rotator cuff repair.